• Extensive stage SCLC (Es-SCLC)
• Extensive stage SCLC (Es-SCLC) - maintenance (M) 2
• Extensive stage SCLC (Es-SCLC) - 1st Line (L1) 5
• Extensive stage SCLC (Es-SCLC) - 2nd line (L2)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• nivolumab based treatment
• nivolumab alone
• Immune checkpoint association
• nivolumab plus ipilimumab

• versus all
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Comparator:  vs placebo; 
Risk of bias:  low;   some concerns;   high;  NA;